¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"high dose rate"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
  • exposure dose
    Æø·Î¼±·®
  • effective dose
    1. À¯È¿¿ë·® 2. À¯È¿¼±·®
  • effective dose equivalent
    À¯È¿¼±·®ÇØ´ç·®
  • erythema dose
    È«¹Ý¼±·®
  • fatal dose
    1. Ä¡»ç¿ë·® 2. Ä¡»ç¼±·®
  • fractional dose
    1. ºÐÇÒ¿ë·® 2. ºÐÇÒ¼±·®
  • immunizing dose
    ¸é¿ª¿ë·®, ¸é¿ª·®
  • individual effective dose
    °³ÀÎÀ¯È¿¿ë·®
  • infective dose
    °¨¿°¿ë·®, °¨¿°·®
  • integral dose
    ÀûºÐ¼±·®
  • lethal dose
    1. Ä¡»ç¿ë·® 2. Ä¡»ç¼±·®
  • loading dose
    ºÎÇϿ뷮, ºÎÇÏ·®
  • low-dose tolerance
    Ç׿ø¼Ò·®Çã¿ë
  • maintenance dose
    À¯Áö¿ë·®
  • minimal effective dose
    ÃÖ¼ÒÀ¯È¿·®
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
  • dose response relationship
    ¿ë·®¹ÝÀÀ°ü°è
  • doubling dose
    ¹è°¡¼±·®
  • effective dose
    À¯È¿¿ë·®, À¯È¿¼±·®
  • erythema dose
    È«¹Ý¼±·®
  • exit dose
    Åë°ú¼±·®
  • exposure dose
    Æø·Î¼±·®
  • fatal dose
    Ä¡»ç¿ë·®, Ä¡»ç¼±·®
  • fractional dose
    ºÐÇÒ¿ë·®, ºÐÇÒ¼±·®
  • immunizing dose
    ¸é¿ª¿ë·®, ¸é¿ª·®
  • individual effective dose
    °³ÀÎÀ¯È¿¿ë·®
  • infective dose
    °¨¿°¿ë·®, °¨¿°·®
  • integral dose
    Àû»ê¹æ»ç¼±·®
  • lethal dose
    Ä¡»ç¿ë·®, Ä¡»ç·®, Ä¡»ç¼±·®
  • loading dose
    ºÎÇϿ뷮, ºÎÇÏ·®
  • maintenance dose
    À¯Áö¿ë·®
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
  • heat transfer rate
    ¿­Àü´Þ·ü(¡­ëÒ).
  • heat transfer rate
    ¿­Àü´Þ·ü(ÊÙËô).
  • hebdomadal death rate
    »ýÈÄÀÏÁÖ°£»ç¸Á·ü(ÊÙË×ËÎËô).
  • incidence rate
    ¹ßº´·ü, ½Åȯ¹ß»ý·ü
  • incidence rate
    ¹ß»ý·ü(ËÑË×Ëô).
  • infant mortality rate
    ¿µ¾Æ»ç¸Á·ü.
  • plasma iron disappearance rate
    Ç÷Àåö¼Ò½Ç·ü(úìíìôÑá¼ã÷ëÒ).
  • plasma iron turnover rate
    Ç÷Àåö±³Ã¼À².
  • postneonatal mortality rate
    ÈĽŻý¾Æ»ç¸Á·ü(Ì·ËàË×ËâË×ËÎËô).
  • pregnancy rate
    ÀÓ½ÅÀ²(ìôããëÒ).
  • prevalence [rate]
    À¯º´·ü
  • prevalence rate
    À¯º´·ü(ËôËÓËô).
  • production rate
    »ý»êÀ²
  • puerperal death rate
    »ê¿å»ç¸Á·ü (ÊÙË×ËÎËô).
  • puerperal death rate
    »êÈÄ»ç¸Á·ü,»ê¿å»ç¸Á·ü (¡­ÞÝØÌëÒ)
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
  • high signal intensity
    °í½ÅÈ£ °­µµ
  • high spatial frequency algorithm
    °í °ø°£ Á֯ļö ¿¬»ê
  • high speed
    °í¼ÓÀÇ
  • high speed core cut biopsy
    °í¼Ó Á᫐ »ý°Ë
  • high spinal anesthesia
    °íÀ§Ã´Ã߸¶Ãë(¹ý).
  • high temperature sterlization
    °í¿Â¸ê±Õ.
  • high tension pulse
    °í¾Ð¸Æ(ÍÔäâØæ), °íÀ可(ÍÔí娿).
  • high tone deafness
    °íÀ½¼º³­Ã»
  • high tracheostomy
    »ó±â°üÀý°³¼ú
  • high vacuum
    °íÁø°ø(°íÁø°ø).
  • high velocity signal loss
    °í¼Óµµ ½ÅÈ£ ¼Ò½Ç
  • high ventricular septal defect
    °íÀ§½É½ÇÁ߰ݰá¼Õ.
  • high vitamin diet
    °íºñŸ¹Î½ÄÀÌ.
  • high voltage radiography
    °íÀü¾Ð ÃÔ¿µ¼ú
  • high volume sampler
    ÇÏÀ̺¼·ý»ùÇ÷¯.
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 6
ADD acceptable daily dose; adduction; adenosine deaminase; attentional deficit disorder; average daily d...
DED date of expected delivery; defined exposure dose; delayed erythema dose
ED early-decision [applicant]; early differentiation; ectodermal dysplasia; ectopic depolarization; eff...
IAD inactivating dose; instructional advance directive; internal absorbed dose
MAD major affective disorder; mandibulo-acral dysplasia; maximum allowable dose; methylandrostenediol; m...
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 6
DLT Dose limiting toxicities
DLT Dose limiting toxicity
DMF Dose modification factors
DRC Dose response curves
DLTs Dose-limiting toxicities
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • immunizing dose
    ¸é¿ª·®
  • intoxicating dose
    Áßµ¶·®, Áßµ¶ ¼±·®
  • least fatal dose
    ÃÖ¼Ò Ä¡»ç·®
    ¾àÁ¦ÀÇ ¿ë·®À» °áÁ¤ÇÏ´Â ½ÇÇè¿¡¼­ 100¸í Áß 1¸íÀÌ¶óµµ »ç¸ÁÇÏ´Â ¹Ù·Î Á÷ÀüÀÇ ¿ë·®.
  • loading dose
    ºÎÇÏ ¿ë·®, ºÎÇÏ·®
  • maintenance dose
    À¯Áö·®, À¯Áö ¿ë·®
    ÀÏÁ¤ÇÑ »óŸ¦ À¯ÁöÇϱâ À§Çؼ­ ÇÊ¿äÇÑ ¾àÁ¦ÀÇ Åõ¿©·®.
  • maximal dose
    ÃÖ´ë ¿ë·®
  • maximum accumulation dose
    ÃÖ´ë ÃàÀû·®
  • maximum tolerance dose
    ÃÖ´ë ³»¿ë·®, ÃÖ´ë °ßµõ ¼±·®
  • mean effective dose
    50% À¯È¿·®
  • mean lethal dose
    50% Ä¡»ç·®
  • mean target dose
    Æò±Õ Ç¥Àû ¼±·®
  • metered-dose inhaler

    methacholine (¸ÞŸÄݸ°

    °­·ÂÇÑ Äݸ° ÀÛµ¿Á¦·Î¼­ ¾Æ¼¼Æ¿Äݸ°°ú °°Àº ÀÛ¿ëÀÌ ÀÖ´Ù.
  • midbreast dose
    À¯¹æ Áß¾Ó Á¶»ç¼±·®
  • minimal dose
    ÃÖ¼Ò·®
  • minimum dose
    ÃÖ¼Ò·®
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 6
high blood pressure <cardiology> Persistently high arterial blood pressure. Hypertension may have no known cause (essential or idiopathic hypertension) or be associated with other primary diseases (secondary hypertension).
This condition is considered a risk factor for the development of heart disease, peripheral vascular disease, stroke and kidney disease.
(29 Sep 1997)
high blood triglyceride <biochemistry> Elevation of triglycerides, a fatty substance found in the bloodstream. Normal triglyceride blood levels should be 10-150 milligrams per decilitre. Elevations of the triglyceride level (particularly in association with elevated cholesterol) have been correlated with the development of atherosclerosis, the underlying cause of heart disease and stroke.
Origin: Gr. Haima = blood
(27 Sep 1997)
high-bred Bred in high life; of pure blood.
Source: Websters Dictionary
(01 Mar 1998)
high-calorie diet A diet containing upward of 4,000 calories per day.
(05 Mar 2000)
high convex The segment of a sphere of short radius.
(05 Mar 2000)
high density lipoprotein <biochemistry> These lipoproteins acts to carry cholesterol in the bloodstream.
Raised high density lipoprotein levels have been correlated with a lower risk for heart disease. Less than 35 mg/dl is considered a positive risk factor for coronary artery disease, over 60 mg/dl is considered a negative risk factor (reduces your risk of heart disease).
Recent studies show a low high density lipoprotein level is the strongest predictor of cardiovascular death in women.
Acronym: HDL
(18 Nov 1997)
high-egg-passage vaccine Living Flury strain rabies virus at the 180th to 190th level egg passage (embryonate eggs), used for vaccination of cattle and cats, low-egg-passage (LEP) vaccine: at the 40th to 50th passage level, containing 103 to 104 mouse LD50; nonpathogenic in dogs but retains some pathogenicity for cattle and cats.
(05 Mar 2000)
high endothelial postcapillary venules Venule's in the lymph nodes, tonsils, and Peyer's patches that have a high-walled endothelium through which blood lymphocytes migrate into the lymphatic parenchyma.
(05 Mar 2000)
high enema An enema instilled high up into the colon.
Synonym: enteroclysis.
(05 Mar 2000)
high energy bond <chemistry> Chemical bonds that release more than 25kJ/mol on hydrolysis: their importance is that the energy can be used to transfer the hydrolysed residue to another compound. The risk in using the term is that students may think the bond itself is different in some way, whereas it is the compound that matters. Hydrolysis of creatine phosphate yields 42.7kJ/mol, of phosphoenolpyruvate, 53.2, ATP to ADP, 30.5: the latter is important because it shows that energetically the hydrolysis of creatine phosphate will suffice to reconstitute ATP, hence the use of creatine phosphate in muscle.
(18 Nov 1997)
high energy compounds Classically, a group of phosphoric esters whose hydrolysis takes place with a standard free energy change of -5 to -15 kcal/mol (or, -20 to -63 kJ/mol) (in contrast to -1 to -4 kcal/mol or, -4 to -17 kJ/mol) for simple phosphoric esters like glucose-6-phosphate or alpha-glycerophosphates), thus being capable of driving energy-consuming reactions in living cells or reconstituted cell-free systems; adenosine 5'-triphosphate, with respect to the beta-and gamma-phosphates, is the best known and is regarded as the immediate energy source for most metabolic syntheses. The general types are acid anhydrides, phosphoric esters of enols, phosphamic acid (R-NH-PO3H2) derivatives, acyl thioesters (e.g., of coenzyme A), sulfonium compound's (R3-S+), and aminoacyl esters of ribosyl moieties.
See: high energy phosphates.
(05 Mar 2000)
high energy particle generating unit A machine capable of providing highly energised radiation for the purposes of radiotherapy treatment.
(16 Dec 1997)
high energy phosphate bond See: high energy phosphates.
(05 Mar 2000)
high energy phosphates Those phosphate's that, on hydrolysis, yield an unusually large amount of energy; e.g., nucleotide polyphosphates such as ATP, enol phosphate's such as phosphoenolpyruvate.
See: high energy compounds.
Synonym: energy-rich phosphates.
(05 Mar 2000)
high-energy shock waves Compression waves of large amplitude, across which density, pressure, and particle velocity change drastically.
(12 Dec 1998)
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
  • high beam
    ÇÏÀ̺ö(¿ø°Å¸®¿ë »óÇâ Çìµå¶óÀÌÆ®)
  • high blood pressure
    °íÇ÷¾Ð
  • high blower
    Äà±èÀ» ¼¼°Ô ³»½¬´Â ¸»
  • high boot
    ÀåÈ­
  • high brass
    =top brass
  • high camp
    ¿¹¼úÀûÀ¸·Î ÁøºÎÇÑ °ÍÀ» ÀǵµÀûÀ¸·Î ÀÌ¿ëÇϱâ
  • high chair
    (¾î¸°ÀÌÀÇ)½Ä»ç¿ë ³ôÀº ÀÇÀÚ
  • high color
    ÁÁÀº Ç÷»ö
  • high comedy
    (¿¬±âÀÇ ÀÍ»ì µûÀ§¿¡ ÁßÁ¡À» µÎÁö ¾Ê´Â)°í±ÞÈñ±Ø
  • high command
    ÃÖ°í »ç·ÉºÎ
  • high commissioner
    (½Ä¹ÎÁöÀÇ)°íµî ÆÇ¹«°ü !
  • high crime
    Áß´ëÇÑ ¹üÁË(´ëÅë·É ±âŸ ÇàÁ¤°üÀÇ ÅºÇÙ ÀÌÀ¯°¡ µÇ´Â ÆÄ·ÅÄ¡ ¹üÁË)
  • high day
    ÃàÁ¦ÀÏ
  • high day
    ÃàÁ¦ÀÏ;°æÃàÀÏ
  • high explosive
    °í¼º´É Æø¾à
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 6
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 6
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 6
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 6
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 6
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 6
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 6
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 6
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 6
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 6
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 6
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 6
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 6
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 6
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 6
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 6
ÅëÇÕ°Ë»ö ¿Ï·á